Nuvectis Pharma (NVCT) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic partnerships and financial position

• Recently completed an in-licensing deal with Haisco Pharmaceuticals, acquiring two compounds: NXP100 (factor B inhibitor) and NXP200 (second-generation BRAF inhibitor).

• Haisco has established credibility through major deals with AbbVie and Eli Lilly and significant venture funding.

• Closed a $150 million financing round, resulting in a current capital position of about $120 million, sufficient to fund operations into the first half of 2029.

Lead asset NXP100: clinical progress and market opportunity

• NXP100 is a once-daily oral factor B inhibitor, offering a convenience advantage over Novartis' twice-daily FABHALTA.

• Approved in China for PNH-naive patients; approval for PNH-experienced patients expected by year-end.

• Demonstrated superior efficacy to C5 inhibitors (SOLIRIS, ULTOMIRIS) in head-to-head studies, with robust increases in hemoglobin and responder rates.

• PNH market projected to grow from over $5 billion to $7–7.5 billion by decade's end, with factor B inhibitors poised to overtake C5s.

• U.S. regulatory pathway includes a pre-IND meeting with the FDA, with pivotal studies expected to start in early 2027.

Expansion into additional indications

• NXP100 phase II data in IgA nephropathy (IgAN) shows proteinuria reduction and eGFR improvement comparable to leading APRIL/BAFFs.

• Ongoing pivotal phase III study in China for IgAN, with readout expected March–April next year.

• Potential for frontline therapy in IgAN due to oral administration and strong efficacy; additional opportunities in lupus and generalized myasthenia gravis (gMG) being explored.

• Haisco is running a phase II lupus study, with results expected by year-end.